International Assets Investment Management LLC Raises Stock Position in Illumina, Inc. (NASDAQ:ILMN)

International Assets Investment Management LLC increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 210.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 48,194 shares of the life sciences company’s stock after buying an additional 32,672 shares during the period. International Assets Investment Management LLC’s holdings in Illumina were worth $6,711,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. J.P. Morgan Private Wealth Advisors LLC acquired a new position in Illumina in the third quarter valued at approximately $29,558,000. Weil Company Inc. boosted its holdings in shares of Illumina by 59.2% in the third quarter. Weil Company Inc. now owns 22,963 shares of the life sciences company’s stock valued at $3,152,000 after acquiring an additional 8,539 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Illumina by 15.0% in the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock valued at $2,466,614,000 after acquiring an additional 2,336,935 shares during the period. Harvest Fund Management Co. Ltd boosted its holdings in shares of Illumina by 60.6% in the third quarter. Harvest Fund Management Co. Ltd now owns 1,246 shares of the life sciences company’s stock valued at $171,000 after acquiring an additional 470 shares during the period. Finally, VisionPoint Advisory Group LLC boosted its holdings in shares of Illumina by 344.6% in the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 193 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Jacob Thaysen purchased 7,330 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was acquired at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the transaction, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the subject of several research analyst reports. Barclays increased their price objective on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. TD Cowen downgraded Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price objective for the company. in a report on Thursday, January 4th. Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Illumina in a report on Wednesday, April 10th. Royal Bank of Canada reissued an “outperform” rating and issued a $253.00 price objective on shares of Illumina in a report on Tuesday, April 9th. Finally, StockNews.com raised Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $167.70.

Illumina Trading Down 2.8 %

NASDAQ:ILMN opened at $127.07 on Monday. The stock has a fifty day moving average price of $135.77 and a two-hundred day moving average price of $128.43. The stock has a market capitalization of $20.24 billion, a price-to-earnings ratio of -17.31 and a beta of 1.19. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $232.88.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the prior year, the business posted $0.14 earnings per share. Illumina’s revenue was up 3.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.